S

Suresh S. Ramalingam

Emory University

ORCID: 0000-0002-0757-3106

Publishes on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. 1.2k papers and 106.2k citations.

PubIndex Score98Top 2%How it's scored

1.2kPublications

106.2kTotal Citations

First publication: 2003First senior author: 2007

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics

Top publicationsby citations

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Vassiliki A. Papadimitrakopoulou, Yi‐Long Wu et al.|New England Journal of Medicine|2016

Cited by 3.3k

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Ferdinandos Skoulidis, Ramaswamy Govindan, Bob T. Li et al.|New England Journal of Medicine|2021

Cited by 1.8k

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Geoffrey R. Oxnard, Myung‐Ju Ahn, Yuichiro Ohe et al.|Annals of Oncology|2020

Cited by 443

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Julie R. Brahmer, Suresh S. Ramalingam, Jong-Seok Lee et al.|Journal of Clinical Oncology|2022

Cited by 375

Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC

Shun Lu, Suresh S. Ramalingam, Terufumi Kato et al.|New England Journal of Medicine|2024

Cited by 291